Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive brain disease characterised by progressive memory loss and cognition impairment, ultimately leading to death. There are three FDA-approved acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine, AChEIs) for the symptomatic treatment of AD....

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Dajiang, Liu, Renzheng, Lv, Yangjing, Guo, Jianan, Zhang, Changjun, Xie, Yuanyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653629/
https://www.ncbi.nlm.nih.gov/pubmed/37955252
http://dx.doi.org/10.1080/14756366.2023.2270781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653629/
https://www.ncbi.nlm.nih.gov/pubmed/37955252
http://dx.doi.org/10.1080/14756366.2023.2270781

Ejemplares similares